These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 11509875)

  • 1. DNA vaccines for hepatitis C virus.
    Brinster C; Inchauspé G
    Intervirology; 2001; 44(2-3):143-53. PubMed ID: 11509875
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting of hepatitis C virus core protein for MHC I or MHC II presentation does not enhance induction of immune responses to DNA vaccination.
    Vidalin O; Tanaka E; Spengler U; Trépo C; Inchauspé G
    DNA Cell Biol; 1999 Aug; 18(8):611-21. PubMed ID: 10463057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effective induction of type 1 cytotoxic T cell responses in mice with DNA vaccine encoding two hepatitis C virus cytotoxic T lymphocyte epitopes.
    Shi L; Liu S; Fan GX; Sheng L; Ren HX; Yuan YK
    Viral Immunol; 2006; 19(4):702-11. PubMed ID: 17201665
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Multiantigenic DNA Vaccine That Induces Broad Hepatitis C Virus-Specific T-Cell Responses in Mice.
    Gummow J; Li Y; Yu W; Garrod T; Wijesundara D; Brennan AJ; Mullick R; Voskoboinik I; Grubor-Bauk B; Gowans EJ
    J Virol; 2015 Aug; 89(15):7991-8002. PubMed ID: 26018154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral immunization with attenuated Salmonella carrying a co-expression plasmid encoding the core and E2 proteins of hepatitis C virus capable of inducing cellular immune responses and neutralizing antibodies in mice.
    Cao J; Chen Z; Ren Y; Luo Y; Cao M; Lu W; Zhao P; Qi Z
    Vaccine; 2011 May; 29(20):3714-23. PubMed ID: 21396407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene vaccination for hepatitis C.
    Inchauspé G
    Springer Semin Immunopathol; 1997; 19(2):211-21. PubMed ID: 9406347
    [No Abstract]   [Full Text] [Related]  

  • 7. Immunogenicity of CIGB-230, a therapeutic DNA vaccine preparation, in HCV-chronically infected individuals in a Phase I clinical trial.
    Alvarez-Lajonchere L; Shoukry NH; Grá B; Amador-Cañizares Y; Helle F; Bédard N; Guerra I; Drouin C; Dubuisson J; González-Horta EE; Martínez G; Marante J; Cinza Z; Castellanos M; Dueñas-Carrera S
    J Viral Hepat; 2009 Mar; 16(3):156-67. PubMed ID: 19017255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic immunization of wild-type and hepatitis C virus transgenic mice reveals a hierarchy of cellular immune response and tolerance induction against hepatitis C virus structural proteins.
    Satoi J; Murata K; Lechmann M; Manickan E; Zhang Z; Wedemeyer H; Rehermann B; Liang TJ
    J Virol; 2001 Dec; 75(24):12121-7. PubMed ID: 11711603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis B virus precore protein augments genetic immunizations of the truncated hepatitis C virus core in BALB/c mice.
    Liao G; Wang Y; Chang J; Bian T; Tan W; Sun M; Li W; Yang H; Chen J; Zhang X; Bi S; Omata M; Jiang S
    Hepatology; 2008 Jan; 47(1):25-34. PubMed ID: 18074356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Immunogenicity and heterologous protection in mice with a recombinant adenoviral-based vaccine carrying a hepatitis C virus truncated NS3 and core fusion protein].
    Guan J; Deng Y; Chen H; Yang Y; Wen B; Tan W
    Bing Du Xue Bao; 2015 Jan; 31(1):7-13. PubMed ID: 25997323
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA-based immunization breaks tolerance in a hepatitis C virus transgenic mouse model.
    Encke J; Geissler M; Stremmel W; Wands JR
    Hum Vaccin; 2006; 2(2):78-83. PubMed ID: 17012868
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo clearance of hepatitis C virus nonstructural 3/4A-expressing hepatocytes by DNA vaccine-primed cytotoxic T lymphocytes.
    Ahlen G; Nystrom J; Pult I; Frelin L; Hultgren C; Sallberg M
    J Infect Dis; 2005 Dec; 192(12):2112-6. PubMed ID: 16288375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CpG immuno-stimulatory motifs enhance humoral immune responses against hepatitis C virus core protein after DNA-based immunization.
    Encke J; zu Putlitz J; Stremmel W; Wands JR
    Arch Virol; 2003 Mar; 148(3):435-48. PubMed ID: 12607097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Induction of cytotoxic T cell responses in mice by immunization with multi-CTL epitope-based anti-HCV DNA vaccine].
    Shi L; Liu S; Sheng L; Meng ZJ; Yuan YK
    Zhonghua Gan Zang Bing Za Zhi; 2006 May; 14(5):385-6. PubMed ID: 16732921
    [No Abstract]   [Full Text] [Related]  

  • 15. N-glycosylation-mutated HCV envelope glycoprotein complex enhances antigen-presenting activity and cellular and neutralizing antibody responses.
    Ren Y; Min YQ; Liu M; Chi L; Zhao P; Zhang XL
    Biochim Biophys Acta; 2016 Aug; 1860(8):1764-75. PubMed ID: 26278021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel combined vaccine candidate containing epitopes of HCV NS3, core and E1 proteins induces multi-specific immune responses in BALB/c mice.
    Zeng R; Li G; Ling S; Zhang H; Yao Z; Xiu B; He F; Huang R; Wei L
    Antiviral Res; 2009 Oct; 84(1):23-30. PubMed ID: 19646486
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel adenovirus type 6 (Ad6)-based hepatitis C virus vector that overcomes preexisting anti-ad5 immunity and induces potent and broad cellular immune responses in rhesus macaques.
    Capone S; Meola A; Ercole BB; Vitelli A; Pezzanera M; Ruggeri L; Davies ME; Tafi R; Santini C; Luzzago A; Fu TM; Bett A; Colloca S; Cortese R; Nicosia A; Folgori A
    J Virol; 2006 Feb; 80(4):1688-99. PubMed ID: 16439526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Whole recombinant yeast-based immunotherapy induces potent T cell responses targeting HCV NS3 and Core proteins.
    Haller AA; Lauer GM; King TH; Kemmler C; Fiolkoski V; Lu Y; Bellgrau D; Rodell TC; Apelian D; Franzusoff A; Duke RC
    Vaccine; 2007 Feb; 25(8):1452-63. PubMed ID: 17098335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of conventional or replicating nucleic acid-based vaccines and recombinant Semliki forest virus-derived particles for the induction of immune responses against hepatitis C virus core and E2 antigens.
    Vidalin O; Fournillier A; Renard N; Chen M; Depla E; Boucreux D; Brinster C; Baumert T; Nakano I; Fukuda Y; Liljeström P; Trépo C; Inchauspé G
    Virology; 2000 Oct; 276(2):259-70. PubMed ID: 11040118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis C virus core protein: an update on its molecular biology, cellular functions and clinical implications.
    Irshad M; Dhar I
    Med Princ Pract; 2006; 15(6):405-16. PubMed ID: 17047346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.